Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

RSV prophylactic population to reach over 15.64 million by 2030 in the 8MM

The Respiratory Syncytial Virus (RSV) prophylactic population in the eight major markets (*8MM) is projected to increase from over 14.55 million cases in 2020 to 15.64 million in 2030, with an annual growth rate (AGR) of 0.75%, according to GlobalData, a leading data and analytics company. The company’s latest report, ‘Respiratory Syncytial Virus (RSV): Epidemiology […]
Read more

Jardiance expected to become preferred treatment in heart failure with preserved ejection fraction

At the 2021 European Society of Cardiology (ESC) Congress, full results were presented for EMPEROR-Preserved, a Phase III trial investigating Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) in heart failure with preserved ejection fraction (HFpEF). The results of this landmark trial are likely to prompt a change in clinical practice for HFpEF, a condition that […]
Read more

Key players in psoriasis offer strong support through branded digital channels to Australian patients, says GlobalData

The psoriasis (PsO) therapeutics market in Australia is dominated by biologics such as anti-TNF, anti-IL-17, anti-IL-23, and anti-IL-12/anti-IL-23 therapies. Among these, stiff competition exists among AbbVie’s Skyrizi, Novartis’ Cosentyx, Eli Lilly’s Taltz and Sun Pharma’s Ilumya. Against this backdrop, the pharma giants offer strong support to PsO patients in the branded space through digital channels, […]
Read more

Ono Pharma Braftovi approval in South Korea will strengthen oncology portfolio but with limited sales potential, says GlobalData

Ono Pharmaceutical’s Braftovi (encorafenib) was recently approved in South Korea as a combination therapy with cetuximab to treat BRAF V600E mutant in previously treated metastatic colorectal cancer (mCRC) patients. However, the limited potential population of BRAF V600E mCRC patients in South Korea is expected to impact its overall sales potential, says GlobalData, a leading data […]
Read more

South Korea’s preferential drug pricing system can boost innovation in pharma research, says GlobalData

South Korea has recently decided to provide practical support to innovative pharmaceutical companies by revising the existing health insurance benefits system. The new system of preferential drug pricing, if designed effectively, can boost innovation in the country’s pharmaceutical research, says GlobalData, a leading data and analytics company. According to GlobalData, the pharmaceutical market in South […]
Read more

Amneal’s IPX-203 shows promising results for motor fluctuations in Parkinson’s disease

Amneal Pharmaceuticals has recently announced that its pipeline product IPX-203 (carbidopa + levodopa, (CD/LD)) achieved key primary and secondary endpoints in the pivotal Phase III RISE-PD clinical trial for patients with Parkinson’s disease (PD) who experience motor fluctuations. Levodopa’s short half-life makes dosing difficult to manage and the treatment is often associated with dyskinesia and […]
Read more

ObsEva’s Yselty provides promise in endometriosis drug market, says GlobalData

Endometriosis is an indication that needs new therapy options. The variety of symptoms across cases, non-specificity of symptoms, and overlap of symptomology with other conditions make it difficult to manage, with cases often being misdiagnosed. According to GlobalData’s Pharma Intelligence Center database, there are 46 pipeline drugs currently being developed for endometriosis worldwide*. The leading […]
Read more

Ardelyx’s tenapanor has potential to capture a slice of the HP market, says GlobalData

The Food and Drug Administration (FDA) recently issued a Complete Response Letter (CRL) to Ardelyx concerning tenapanor’s New Drug Application (NDA) for chronic kidney disease (CKD)–hyperphosphatemia (HP). If eventually approved, tenapanor has the potential to capture a slice of the HP market by targeting dialysis-dependent patients who are not able to maintain recommended phosphate levels, […]
Read more

Vertex and AbbVie are the only current and future players in the cystic fibrosis market, says GlobalData

The disease-modifying nature of cystic fibrosis transmembrane conductance regulator (CFTR) modulators has transformed the treatment paradigm for cystic fibrosis (CF) over the last decade, a trend that is likely to persist to 2030, and will greatly improve the quality of life and longevity of patients, according to GlobalData. The leading data and analytics company notes […]
Read more

Increased use of virtual trials has contributed to improved patient accrual rates, says GlobalData

The increased use of virtual components such as eConsent, telemedicine, remote patient monitoring and wearables in clinical trials over the past decade has led to fewer trial delays or terminations due to low participant numbers says GlobalData, a leading data and analytics company. According to GlobalData’s report, ‘Virtual Clinical Trials – Thematic Research’, COVID-19 lockdowns […]
Read more
1 … 58 59 60 61 62 … 110